Affordable Access

deepdyve-link
Publisher Website

RTP801 is a critical factor in the neurodegeneration process of A53T α-synuclein in a mouse model of Parkinson's disease under chronic restraint stress.

Authors
  • Zhang, Zhao1
  • Chu, Shi-Feng1
  • Wang, Sha-Sha1, 2
  • Jiang, Yi-Na3
  • Gao, Yan1
  • Yang, Peng-Fei1
  • Ai, Qi-Di3
  • Chen, Nai-Hong1, 3, 4, 2
  • 1 State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica & Neuroscience Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. , (China)
  • 2 School of Basic Medicine, Shanxi University of Traditional Chinese Medicine, Shanxi, China. , (China)
  • 3 College of Pharmacy, Hunan University of Chinese Medicine, Changsha, China. , (China)
  • 4 Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China. , (China)
Type
Published Article
Journal
British Journal of Pharmacology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Feb 01, 2018
Volume
175
Issue
4
Pages
590–605
Identifiers
DOI: 10.1111/bph.14091
PMID: 29130486
Source
Medline
License
Unknown

Abstract

RTP801 is a promising target for the treatment of PD, especially for PD-sensitive patients who live under increased social pressure. Down-regulation of RTP801 could inhibit the current tendency to an earlier onset of PD.

Report this publication

Statistics

Seen <100 times